Blinatumomab as salvage therapy in patients with relapsed/refractory B-ALL who have failed/progressed after anti-CD19-CAR T therapy

BACKGROUND: Anti-CD19 chimeric antigen receptors (CARs) T-cell therapy has been shown to have excellent efficacy in patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (ALL). But many patients are refractory to anti-CD19-CAR T-cell therapy or relapse again. METHODS: Five pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Qi, Yao, Liu, Hong, Li, Xin, Shi, Yin, Mu, Juan, Li, Jingyi, Wang, Ying, Deng, Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Hematology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332179/
https://www.ncbi.nlm.nih.gov/pubmed/37417690
http://dx.doi.org/10.1080/07853890.2023.2230888

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332179/
https://www.ncbi.nlm.nih.gov/pubmed/37417690
http://dx.doi.org/10.1080/07853890.2023.2230888

Ejemplares similares